139 related articles for article (PubMed ID: 37019745)
21. The Impact of Highly Effective Cystic Fibrosis Transmembrane Conductance Regulator Modulators on the Health of Female Subjects With Cystic Fibrosis.
Taylor-Cousar JL; Shteinberg M; Cohen-Cymberknoh M; Jain R
Clin Ther; 2023 Mar; 45(3):278-289. PubMed ID: 36841738
[TBL] [Abstract][Full Text] [Related]
22. CFTR mutations and cystic fibrosis.
Prescrire Int; 2013 Oct; 22(142):232. PubMed ID: 24298580
[No Abstract] [Full Text] [Related]
23. Ivacaftor in a G551D homozygote with cystic fibrosis.
Harrison MJ; Murphy DM; Plant BJ
N Engl J Med; 2013 Sep; 369(13):1280-2. PubMed ID: 24066763
[No Abstract] [Full Text] [Related]
24. Therapy for cystic fibrosis--the end of the beginning?
Davis PB
N Engl J Med; 2011 Nov; 365(18):1734-5. PubMed ID: 22047565
[No Abstract] [Full Text] [Related]
25. Body composition in children with cystic fibrosis treated with CFTR modulators versus modulator naïve individuals.
Dress C; Hente E; Hossain MM; Hardie W; Hjelm M; Boat T
Pediatr Pulmonol; 2024 Mar; 59(3):805-808. PubMed ID: 38116856
[No Abstract] [Full Text] [Related]
26. Elexacaftor-tezacaftor-ivacaftor overdose in an adolescent female with cystic fibrosis.
Lyman BC; Seay J; Contreary C; Savant AP; Dell ML; Hescock GC
Pediatr Pulmonol; 2022 Dec; 57(12):3174-3176. PubMed ID: 35962539
[No Abstract] [Full Text] [Related]
27. Ivacaftor withdrawal syndrome: A potentially life-threatening consequence from a life-saving medication.
Clegg JM; Malloy KW; Brown RF; Grisso AG; Sokolow AG
J Cyst Fibros; 2022 May; 21(3):549-550. PubMed ID: 34391678
[No Abstract] [Full Text] [Related]
28. Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation.
Trimble AT; Donaldson SH
J Cyst Fibros; 2018 Mar; 17(2):e13-e16. PubMed ID: 29079142
[TBL] [Abstract][Full Text] [Related]
29. Optimising the care and quality of life of people with cystic fibrosis: the influence of cystic fibrosis transmembrane conductance regulator modulators.
Shaw N; Collins S; Smith T; McCulloch A; Ketchell I; Edwards V; Blaikie L; Daniels T
Br J Hosp Med (Lond); 2021 Nov; 82(11):1-6. PubMed ID: 34817261
[TBL] [Abstract][Full Text] [Related]
30. Prenatal Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Promising Way to Change the Impact of Cystic Fibrosis.
Gómez-Montes E; Salcedo Lobato E; Galindo Izquierdo A; García Alcázar D; Villalain González C; Moral-Pumarega MT; Bustos Lozano G; Luna-Paredes C
Fetal Diagn Ther; 2023; 50(2):136-142. PubMed ID: 36996799
[TBL] [Abstract][Full Text] [Related]
31. Evidence for Early Cystic Fibrosis Transmembrane Conductance Regulator Modulator Treatment for Children with Cystic Fibrosis Keeps Growing.
Hoppe JE; Zemanick ET; Martiniano SL
Am J Respir Crit Care Med; 2022 Dec; 206(11):1308-1310. PubMed ID: 35947636
[No Abstract] [Full Text] [Related]
32. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor.
Graeber SY; Hug MJ; Sommerburg O; Hirtz S; Hentschel J; Heinzmann A; Dopfer C; Schulz A; Mainz JG; Tümmler B; Mall MA
Am J Respir Crit Care Med; 2015 Nov; 192(10):1252-5. PubMed ID: 26568242
[No Abstract] [Full Text] [Related]
33. Successful Pregnancy of a Patient with Cystic Fibrosis Genotype F508del/ F508del and Progressed Pulmonary Destruction on lumacaftor/ivacaftor.
Mainz JG; Michl RK; Beiersdorf N; Lorenz M; Schneider U; Groten T; Jaudszus A
Klin Padiatr; 2019 Sep; 231(5):271-273. PubMed ID: 31408905
[No Abstract] [Full Text] [Related]
34. [A milestone in cystic fibrosis therapy].
Reinhardt D
MMW Fortschr Med; 2015 Nov; 157(19):34. PubMed ID: 26953403
[No Abstract] [Full Text] [Related]
35. Another Beginning for Cystic Fibrosis Therapy.
Davis PB
N Engl J Med; 2015 Jul; 373(3):274-6. PubMed ID: 25981385
[No Abstract] [Full Text] [Related]
36. A Review on the Use of Cystic Fibrosis Transmembrane Conductance Regulator Gene Modulators in Pediatric Patients.
Bitonti M; Fritts L; So TY
J Pediatr Health Care; 2019; 33(3):356-364. PubMed ID: 31029283
[TBL] [Abstract][Full Text] [Related]
37. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Ong T; Ramsey BW
Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
[TBL] [Abstract][Full Text] [Related]
38. A new chapter in therapy for cystic fibrosis.
Bilton D
Lancet Respir Med; 2015 Jul; 3(7):e20. PubMed ID: 26117158
[No Abstract] [Full Text] [Related]
39. Cystic Fibrosis-Asthma Overlap Syndrome. Combination of Cystic Fibrosis Transmembrane Conductance Regulator Modulators and Type 2 Targeted Biologic Treatment for Asthma.
Jiménez-Gómez M; Díaz Campos RM; Diab Cáceres L
Arch Bronconeumol; 2023 Aug; 59(8):512-513. PubMed ID: 37127448
[No Abstract] [Full Text] [Related]
40. Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor.
Munce D; Lim M; Akong K
Pediatr Pulmonol; 2020 Dec; 55(12):3381-3383. PubMed ID: 32910556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]